

FREEDOM OF INFORMATION REQUEST

RF23-710

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested. Please see the response in bold below.

In the past three months, how many patients have been treated for Colorectal Cancer [CRC] with the following regimens? If possible, please also provide the split of metastatic vs non-metastatic patients for each regimen.

Regimens	Total patients	Metastatic patients	Non-Metastatic patients
Capecitabine	27	11	16
CAPIRI	6	6	0
CAPOX	45	15	30
Cetuximab with FOLFIRI	16	16	0
Cetuximab with FOLFOX	1	1	0
Cetuximab as a single agent	0	0	0
Cetuximab with Encorafenib	5	5	0
Irinotecan as a single agent	0	0	0
FOLFIRI	53	50	3
FOLFOX	49	36	13
Fluorouracil (5FU) as a single agent	0	0	0
Oxaliplatin as a single agent	0	0	0
Nivolumab with Ipilimumab	1	1	0
Panitumumab with FOLFIRI	10	10	0
Panitumumab with FOLFOX	0	0	0
Panitumumab as a single agent	0	0	0
Pembrolizumab	8	6	2
Any other systemic anti-cancer therapy	36	26	10
Palliative care only	Unknown*	Unknown*	Unknown*

EKHUFT regret we are unable to answer this question as this data is not recorded in ARIA e-prescribing pharmacy system.

(DATE OF RESPONSE: 27 NOVEMBER 2023)